SCHEMBL14839559

SCHEMBL14839559

c1ccc(Oc2ccccc2C2COCCN2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 10/20 0.50
▸ SLC6A4 P31645 10/20 0.50
▸ SLC6A3 Q01959 10/20 0.50
▸ HTR1A P08908 9/20 0.50
▸ KDM1A O60341 2/20 0.45
▸ NTRK1 P04629 1/20 0.34
▸ NTRK3 Q16288 1/20 0.34
▸ NTRK2 Q16620 1/20 0.34
▸ PRKACA P17612 1/20 0.33
▸ PRKACG P22612 1/20 0.33
▸ PRKACB P22694 1/20 0.33
▸ NCOA1 Q15788 1/20 0.33
▸ NCOA3 Q9Y6Q9 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL14830108 0.89 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3HTR1AKDM1A
SCHEMBL14839568 0.79 KCNH2 (0.43) SLC6A2SLC6A3KDM1APRKACAPRKACG
SCHEMBL25235278 0.78 SMN1; SMN2 (0.40) HTR1A
SCHEMBL25237779 0.78 SMN1; SMN2 (0.40) HTR1A
SCHEMBL11509481 0.77 HTR1A (0.58) SLC6A2SLC6A4SLC6A3HTR1AKDM1A
SCHEMBL24005407 0.73 PRKACA (0.36) SLC6A2SLC6A4SLC6A3HTR1APRKACA
SCHEMBL5054635 0.73 HTR2A (0.37) PRKACAPRKACGPRKACBPOLB
SCHEMBL23136984 0.73 PRKACA (0.45) SLC6A2SLC6A3PRKACAPRKACGPRKACB
SCHEMBL29748038 0.73 HTR2C (0.43) SLC6A2SLC6A3KDM1APRKACAPRKACG
SCHEMBL30463847 0.73 PRKACA (0.45) SLC6A2SLC6A3PRKACAPRKACGPRKACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751088-B1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2016-04-13 — — EP disclosed
US-8765751-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-01 — — US disclosed
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 — — US disclosed
WO-2013049719-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089624-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, PLK1 SLC6A2 4134/4885SLC6A4 4373/4885SLC6A3 4197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback